TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00373581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vigabatrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Study: NCT03228108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: see study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: see study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: see study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: see study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinam/augmentin
Description: see study arms.
Study: NCT00730158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD018
Description: Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
Study: NCT02185703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chordate System S020 in treatment mode

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Chordate System S020 in placebo mode
Study: NCT03360266

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with CPP-ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride with CPP-ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sodium fluoride with ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride with ACP varnish
Description: for children with ECC, this varnish effectively remineralizes the white spot lesion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride Varnish
Description: ffor children with ECC, this varnish effectively remineralizes the white spot lesion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride Varnish
Description: ffor children with ECC, this varnish effectively remineralizes the white spot lesion
Study: NCT01388517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
Study: NCT02738008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study: NCT00420576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBT-Danggui Buxue Tang
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBT-Danggui Buxue Tang
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBT-Danggui Buxue Tang
Description: Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
Study: NCT05413746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reoxcare antioxidant dressing
Description: After wound cleaning activities, wound bed debridement if necessary and elimination of hyperkeratotic edges, wounds are treated with Reoxcare as primary dressing and the approppriate secondary dressing for adequate exudates management
Study: NCT02028481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative air tamponade
Description: Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
Study: NCT03550378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Participants will receive subcutaneous MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo matched to MEDI0382 once daily for 32 days.
Study: NCT02988778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonid 50mcg (Noex)
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonid 50mcg (Busonid)
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study: NCT01092728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: 100 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: 100 mg daily.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Complete surgical resection of tumor(s).
Study: NCT04283305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality approach avoidance training
Description: In the VR-based AAT, patients are situated in a bar environment where drinks appear on a bar table in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a controller, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based approach avoidance training
Description: In the computer-based AAT, patients are situated in front of a computer where drinks appear on the screen in front of them. Patients are instructed to react to 100% of the alcoholic beverages with a push response with a joystick, and to non-alcoholic drinks in 100% of the trials with a pull response. The stimuli set consists of 50 different beverages, which are displayed three times in total.
Study: NCT02526277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MMF07 Foot Massager

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MMF07 Foot Massager

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy
Study: NCT03477734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS1 & heart monitor
Description: Daily activities while wearing the investigational device as well as the control device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CS1 & heart monitor
Description: Daily activities while wearing the investigational device as well as the control device
Study: NCT03790566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5 ml/kg 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg 0.25% bupivacaine
Study: NCT03502837

Intervention type: OTHER
Intervention: emotional sound and neutral sound
Description: Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli.

Intervention type: OTHER
Intervention: emotional sound and neutral sound
Description: Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli.

Intervention type: OTHER
Intervention: emotional sound and neutral sound
Description: Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli.
Study: NCT00830544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Neoadjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Experimental chemotherapy regimen
Study: NCT03409614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810/chemo/ipi
Description: REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1

Intervention type: OTHER
Group type: OTHER
Intervention: Chemotherapy
Description: Platinum-based doublet chemotherapy Part 1

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching placebo Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo Part 2
Study: NCT02670486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audiovisual stimulus
Description: Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
Study: NCT02107066

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
Study: NCT02222571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Tots Together Program
Description: Group-based parenting program, 9 weeks delivered in a community setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervision for Safety
Description: group-based safety intervention for parents
Study: NCT02166892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specially designed plates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specially designed plates
Study: NCT01140841

Intervention type: DRUG
Intervention: Fipamezole ODT
Description: Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.

Intervention type: DRUG
Intervention: Placebo
Description: 1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
Study: NCT02812836

Intervention type: DEVICE
Group type: OTHER
Intervention: Manometry
Description: Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
Study: NCT02319941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Study: NCT03226717

Intervention type: DRUG
Intervention: Antiviral agents
Description: combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
Study: NCT06187259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caries removal by carbide bur
Description: caries was removed using a slow-speed handpiece and round carbide burs in sizes #12, #14, and #16, based on the lesion's size. When hard dentin was found using a dental probe, carious dentin removal was stopped.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: caries removal by polymer bur II
Description: carious tissue was removed utilizing smart polymer burs of sizes #4, #6, and #8, depending on the cavity's size, running at a slow speed without water coolant, in circular motions from the center of the lesion outward. Carious dentin removal ceased when the instrument became macroscopically abraded and sharpened and could no longer remove tooth tissues.
Study: NCT02972060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.
Study: NCT01627977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dye of Lutein, Zeaxanthin and Brilliant Blue
Description: dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
Study: NCT01918124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and Doxorubicin and Cyclophosphamide
Description: Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
Study: NCT04247386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Mizone
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 0.6LMizone and 0.4L water.~On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 1.2LMizone and 0.8L water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS
Description: The evening before the colonoscopy:60gPEG-4000 was mixed with 1L water. On the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 2L water.
Study: NCT03062735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory Muscle Training
Description: The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
Study: NCT02758717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03767647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence lessons
Description: 6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
Study: NCT02734693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 4mg
Description: dasotraline 4mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo/day
Study: NCT02050477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Vertical Gastroplasty
Description: The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
Study: NCT02647307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: Single 12-hour intravenous infusion of DS-1040b (20 mg)
Study: NCT01480661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 500 µg, once a day in the morning during 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Roflumilast
Description: Placebo 500 µg, once a day in the morning during 6 months

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT scan of thorax, at baseline and after 6 months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Functional Respiratory Imaging
Description: CT scan of thorax, at baseline and after 6 months
Study: NCT03918616

Intervention type: DRUG
Intervention: Memantine, Dopamine receptor-agonists
Description: The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
Study: NCT00837902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol (β-blocker)
Description: 25 mg tablet
Study: NCT01869738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard Prime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (BMS/DES)
Study: NCT01832077

Intervention type: DEVICE
Intervention: 90 D
Description: rural doctors exam eye fundus by 90 D

Intervention type: DEVICE
Intervention: fundus camera and grader
Description: taking fundus pictures and graded by graders in ZOC
Study: NCT02005016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naming therapy
Description: Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
Study: NCT04622111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride 750 mg
Description: IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
Study: NCT02151487

Intervention type: DRUG
Intervention: Ropivacaine
Description: Ropivacaine alone

Intervention type: DRUG
Intervention: Ropivacaine and dexamethasone
Description: Ropivacaine combination with dexamethasone

Intervention type: DRUG
Intervention: Ropivacaine and clonidine
Description: Ropivacaine combination with clonidine

Intervention type: DRUG
Intervention: Ropivacaine, dexamethasone and clonidine
Description: Ropivacaine combination with dexamethasone and clonidine